SOURCE: Bio-Matrix Scientific Group, Inc.

January 14, 2015 08:30 ET

Regen BioPharma, Inc. Provides Update on Company's Progress and Areas of Specialization for 2015

SAN DIEGO, CA--(Marketwired - Jan 14, 2015) - Regen BioPharma Inc. (OTCBB: RGBP) provided the following update on the Company's direction for 2015:

The Company currently has augmented its activities in the area of gene silencing for treating cancer with two complimentary approaches. One approach silences indoleamine 2,3 -- dioxygenase (IDO) allowing the body's own immune system to attack cancer. IDO is associated with immune-suppression and is over-expressed in cancer. The second approach targets cancer stem cells, the goal of which is to change these cells into mature non-cancerous cells through the utilization of small molecules, gene silencing / gene editing and telomere manipulation.

This is a novel paradigm in cancer therapy as it avoids the use of harsh treatments such as chemotherapy and radiation. The Company believes this double-barreled treatment will be safer than conventional cancer therapies and will result in fewer side effects while demonstrating a higher degree of efficacy than current conventional therapies. The Company's reason for this belief is that its approach targets eradicating the "root" of the cancer, which is the cancer stem cell.

The Company currently has an IND (Investigational New Drug Application #16200) filed with the FDA on, the Company's gene silencing product known as dCellVax. This product draws on technology developed by Regen as well as technology licensed from Benitec Biopharma Ltd. The Company's second gene silencing / gene editing platform which targets cancer stem cells derives from technology acquired from the University of Toronto based on work conducted by Dr. Christine Ichim and Dr. Richard Wells, and is being developed by Regen BioPharma. 

The Company also has an IND filed with the FDA on its HemaXellerate product for treating aplastic anemia (#15376). This product uses a patient's own stem cells to stimulate the production of blood. Currently FDA is reviewing protocols submitted by the Company for conducting an additional GLP safety study before clinical trials can begin.

David Koos, Chairman & CEO of Regen BioPharma, noted, "We are focused on treating cancer from several angles, incorporating gene silencing, immunotherapy, small molecules and telomere manipulation. Our approach to aplastic anemia should give hope to those suffering from this disease. I believe our interest in telomeres and small molecule therapies will allow us to address diseases that are not currently treated effectively or clearly understood."

A Company Spokesperson stated that updates have been made to Regen's website including a full discussion of its ongoing research under "Product Pipeline" and a listing of "Intellectual Property." These links can be found at

ABOUT REGEN BIOPHARMA INC.: Regen BioPharma Inc. is a publicly traded biotechnology company (OTCBB: RGBP). The Company is focused on identifying undervalued regenerative medicine applications in the stem cell space and rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. Currently the Company is focused on gene silencing therapy for treating cancer, telomeres and small molecule therapies, along with developing stem cell treatments for aplastic anemia. Regen is majority owned by Bio-Matrix Scientific Group Inc. (OTC PINK: BMSN).

Disclaimer: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

Contact Information

  • Contact:

    Regen BioPharma Inc.
    David R. Koos, PhD
    Chairman & Chief Executive Officer